GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates

Paris, France, Thursday January 8, 2026, 6:00 pm CEST – GenSight Biologics (“GenSight Biologics” or the “Company“) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2025, and provided business updates.

Cash Position and Outlook

As of December 31, 2025, GenSight Biologics’ cash and cash equivalents totaled €2.4 million, up from €0.6 million as of September 30. This increase reflects the partial funds from the €2.9 million capital increase on December 26, which were received prior to the end of the year.

On January 7, 2026, the company received the remaining proceeds from the December fundraising. After repaying €0.7 million of the principal on the convertible bonds held by Heights Capital, GenSight Biologics’ cash and cash equivalents totaled €2.9 million.

The company has sufficient net working capital to meet its obligations through February 2026. Revenues from the compassionate access programs in France and Israel should then at a minimum ensure the Company’s operational continuity through 2026. Beyond this baseline, the Company will continue its funding operations, on a dilutive and non-dilutive basis, to further extend the cash runway and in particular to finance the RECOVER Phase III trial.

Business Updates

The GS010 manufacturing process, which was transferred to the Company’s new CDMO, is now locked at the CDMO. Final confirmation of the successful technology transfer will be obtained from an engineering run scheduled for Q1 2026.

The REVISE Study, approved by the French agency ANSM in December 2025, has now received all final approvals. The study is on track to begin in January 2026.

Following approval of individual patient early access treatments by the ANSM and Israeli Ministry of Health in December 2025, the Company is working to fulfill the administrative requirements for proceeding with the treatments. The Company expects to begin receiving payments for early access treatments in Q1 2026.

The Company’s primary strategic focus remains on preparing for the start of the RECOVER Phase III study in H2 2026, while pursuing opportunities to out-license GS010 in markets outside the USA and Europe and exploring paid Early Access Programs worldwide.

CFO Jan Eryk Umiastowski will represent the company at the 44th Annual J.P. Morgan Healthcare Conference, to be held this year from January 12-15 in San Francisco, CA, USA.

Share Information

As of January 8, 2026, GenSight Biologics had 220,890,398 outstanding ordinary shares.